Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gatifloxacin - AbbVie/Senju Pharmaceutical

Drug Profile

Gatifloxacin - AbbVie/Senju Pharmaceutical

Alternative Names: AM 1155; BMS 206584; Bonoq; Bonoq Uro; CG 5501; Gatiflo; Gesetz; Tequin; Zymar; Zymaxid

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyorin Pharmaceutical
  • Developer AbbVie; Allergan; Kyorin Pharmaceutical; Senju Pharmaceutical
  • Class Antibacterials; Fluoroquinolones; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Infectious conjunctivitis
  • Market Withdrawal Acute exacerbations of chronic bronchitis; Bacterial infections; Chlamydial infections; Gonorrhoea; Pneumonia; Respiratory tract infections; Sinusitis; Skin and soft tissue infections; Urinary tract infections
  • Discontinued Anthrax; Otitis media

Most Recent Events

  • 01 Feb 2023 Regulatory submission withdrawn for Infectious conjunctivitis in China (Ophthalmic)
  • 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
  • 08 May 2020 Allergan has been acquired and merged into AbbVie
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top